Physician profile
Jonathan D Rhoads
NPI 1073560066
$4,230.70
in general payments reported to CMS, 2019-2025
29 companies · $967 in 2025
The $967 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $475 · 2022: $835 · 2023: $899 · 2024: $1,054 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,920.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $762.44 | 2021-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $527.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $376.68 | 2021-2025 | Wainua, Farxiga, Evusheld |
| Pfizer INC. | $352.56 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $312.86 | 2021-2025 | Lifevest |
| Abbott Laboratories | $221.55 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Daiichi Sankyo INC. | $179.14 | 2022-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $150.19 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $148.52 | 2021 | |
| Alnylam Pharmaceuticals INC. | $148.49 | 2024-2025 | Onpattro |
| Philips North America LLC | $115.34 | 2022-2024 | (5050) Extended Holter |
| Amgen INC. | $112.16 | 2022-2024 | Repatha |
| Bridgebio Pharma, INC. | $111.73 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $100.11 | 2024 | Optimizer |
| Janssen Pharmaceuticals, INC | $93.76 | 2021-2024 | Xarelto |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $85.50 | 2023 | Evkeeza |
| Novo Nordisk INC | $71.69 | 2024-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.06 | 2023-2025 | Jardiance |
| Amarin Pharma, INC. | $40.81 | 2021-2022 | |
| Scpharmaceuticals INC. | $38.81 | 2024 | |
| Vifor Pharma, INC. | $29.45 | 2021 | |
| Sanofi-Aventis U.S. LLC | $29.43 | 2023 | |
| Medtronic, INC. | $27.37 | 2022 | |
| Esperion Therapeutics, INC. | $24.60 | 2021 | |
| Abiomed | $23.43 | 2025 | |
| Cleerly, INC. | $21.32 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Bayer Healthcare Pharmaceuticals INC. | $20.73 | 2025 | |
| Xeris Pharmaceuticals, INC. | $18.96 | 2025 | Keveyis |
| Cvrx, INC. | $18.46 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Rhoads listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.